Reva implants first Fantom bioresorbable scaffold in Italy

Reva Medical (ASX:RVA) said yesterday that the first Fantom bioresorbable scaffold was implanted in Italy.

The sirolimus-eluting device is made using a tyrosine-derived polymer that is visible under x-ray. Data from Reva’s Fantom II clinical trial found that the device resulted in a 4.2% rate of major adverse cardiac events after 12 months and 5.6% after 24 months.

Get the full story at our sister site, Drug Delivery Business News.

The post Reva implants first Fantom bioresorbable scaffold in Italy appeared first on MassDevice.

from MassDevice http://ift.tt/2Bv73aU